Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study
Castillo et al.
, Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care..
, Journal of Steroid Biochemistry and Molecular Biology, 203, October 2020, doi:10.1016/j.jsbmb.2020.105751
RCT on calcifediol (25-hydroxyvitamin D) treatment for hospitalized COVID-19 patients showing significantly reduced intensive care unit admissions. All patients received standard care including HCQ+AZ. Significantly lower ICU admission with the addition of calcifediol - adjusted odds ratio 0.03 [0.003-0.25]. No deaths for calcifediol (0/50), 2 deaths for SOC (2/26).
Castillo et al., 29 Aug 2020, peer-reviewed, 7 authors.
Abstract: Since January 2020 Elsevier has created a COVID-19 resource centre with
free information in English and Mandarin on the novel coronavirus COVID19. The COVID-19 resource centre is hosted on Elsevier Connect, the
company's public news and information website.
Elsevier hereby grants permission to make all its COVID-19-related
research that is available on the COVID-19 resource centre - including this
research content - immediately available in PubMed Central and other
publicly funded repositories, such as the WHO COVID database with rights
for unrestricted research re-use and analyses in any form or by any means
with acknowledgement of the original source. These permissions are
granted for free by Elsevier for as long as the COVID-19 resource centre
Journal of Steroid Biochemistry and Molecular Biology 203 (2020) 105751
Contents lists available at ScienceDirect
Journal of Steroid Biochemistry and Molecular Biology
journal homepage: www.elsevier.com/locate/jsbmb
“Effect of calcifediol treatment and best available therapy versus best
available therapy on intensive care unit admission and mortality among
patients hospitalized for COVID-19: A pilot randomized clinical study”
Marta Entrenas Castillo a, Luis Manuel Entrenas Costa a, *, José Manuel Vaquero Barrios a,
Juan Francisco Alcalá Díaz b, José López Miranda b, Roger Bouillon c,
José Manuel Quesada Gomez d
UGC de Neumología, Instituto Maimónides de Investigación Biomédica de Córdoba 9 (IMIBIC). Hospital Universitario Reina Sofía, Universidad de Córdoba, Avda.
Menéndez 10 Pidal s/n, 14004 11, Córdoba, Spain
Departamento de Medicina Interna. IMIBIC, CIBER de Fisiopatología de la Obesidad y la Nutrición. Hospital Universitario Reina Sofía, Universidad de Córdoba,
Fundación Progreso y Salud. Avda. Menéndez Pidal s/n, 14004 14, Córdoba, Spain
Department of Chronic Diseases, Metabolism and Ageing, Laboratory of Clinical and Experimental Endocrinology, KU Leuven, Herestraat, ON1/902, 3000, Leuven,
IMIBIC. CIBER de Fragilidad y Envejecimiento Saludable. Hospital Universitario Reina Sofía, Universidad de Córdoba, Fundación Progreso y Salud. Avda. Menéndez
Pidal s/n, 18 14004, Córdoba, Spain
A R T I C L E I N F O
A B S T R A C T
Vitamin D3 or cholecalciferol
Calcifediol or 25-hydroxyvitamin D3
1α, 25(OH)2D or 1α, 25-dihydroxyvitamin D or
Acute respiratory distress syndrome (ARDS)
Vitamin D endocrine system
Cuboidal alveolar coating cells type II
TLR co-receptor CD14
Vitamin D receptor
Objective: The vitamin D endocrine system may have a variety of actions on cells and tissues involved in COVID19 progression especially by decreasing the Acute Respiratory Distress Syndrome. Calcifediol can rapidly in
crease serum 25OHD concentration. We therefore evaluated the effect of calcifediol treatment, on Intensive Care
Unit Admission and Mortality rate among Spanish patients hospitalized for COVID-19.
Design: Parallel pilot randomized open label, double-masked clinical trial.
Setting: University hospital setting (Reina Sofia University Hospital, Córdoba Spain.)
Participants: 76 consecutive patients hospitalized with COVID-19 infection, clinical picture of acute respiratory
infection, confirmed by a radiographic pattern of viral pneumonia..
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC
provide treatment protocols.